

02-61000-35

Original Effective Date: 07/15/08

Reviewed: 06/27/24

Revised: 07/15/24

Subject: Endovascular Procedures for Intracranial Arterial Disease (Atherosclerosis and Aneurysms) and Extracranial Vertebral Artery Disease

THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION OF BENEFITS, OR A GUARANTEE OF PAYMENT, NOR DOES IT SUBSTITUTE FOR OR CONSTITUTE MEDICAL ADVICE. ALL MEDICAL DECISIONS ARE SOLELY THE RESPONSIBILITY OF THE PATIENT AND PHYSICIAN. BENEFITS ARE DETERMINED BY THE GROUP CONTRACT, MEMBER BENEFIT BOOKLET, AND/OR INDIVIDUAL SUBSCRIBER CERTIFICATE IN EFFECT AT THE TIME SERVICES WERE RENDERED. THIS MEDICAL COVERAGE GUIDELINE APPLIES TO ALL LINES OF BUSINESS UNLESS OTHERWISE NOTED IN THE PROGRAM EXCEPTIONS SECTION.

Position Statement	Billing/Coding	Reimbursement	Program Exceptions	Definitions	Related Guidelines
Other	References	Update			

DESCRIPTION:

Intracranial Arterial Disease

Cerebrovascular diseases include a range of processes affecting the cerebral vascular system, including arterial thromboembolism, arterial stenosis, and arterial aneurysms, all of which can restrict cerebral blood flow due to ischemia or hemorrhage. Endovascular techniques, including endovascular mechanical embolectomy with various devices types of devices (ie, stents), and angioplasty with or without stenting have been investigated for the treatment of cerebrovascular diseases.

Intracranial arterial disease includes thromboembolic events, vascular stenoses, and aneurysms. Endovascular techniques have been investigated for the treatment of intracranial arterial disease. Endovascular therapy is used as an alternative or adjunct to intravenous tissue plasminogen activator and supportive care for acute stenosis and as an adjunct to risk-factor modification for chronic stenosis.

For cerebral aneurysms, stent-assisted coiling and the use of flow-diverting stents have been evaluated as an alternative to endovascular coiling in patients whose anatomy is not amenable to simple coiling.

Several devices for endovascular treatment of intracranial arterial disease have been cleared for marketing by the U .S. Food and Drug Administration (FDA) through the 510(k) process or the humanitarian device exemption (HDE) process.

Extracranial Vertebral Artery Disease

Vertebral artery diseases, including atherosclerotic stenosis, dissections, and aneurysms, can lead to ischemia of the posterior cerebral circulation. Conventional management of extracranial vertebral artery diseases may include medical therapy (eg, antiplatelet or anticoagulant medications), medications to reduce atherosclerotic disease risk (eg, statins), and/or surgical revascularization.

The management of extracranial vertebral artery aneurysms or dissections is controversial due to uncertainty about the risk of thromboembolic events associated with aneurysms and dissections. Antiplatelet therapy is typically used; surgical repair, which may include vertebral bypass, external carotid autograft, and vertebral artery transposition to the internal carotid artery, or endovascular treatment with stent placement or coil embolization, may also be used. Given the technical difficulties related to surgical access of the extracranial vertebral artery, endovascular therapies have been investigated for extracranial vertebral artery disease. Endovascular therapy may consist of percutaneous transluminal angioplasty (PTA), with or without stent implantation.

POSITION STATEMENT:

Intracranial Arterial Disease

Note: The intracranial arterial disease position statements are not intended to address the use of rescue endovascular therapies, including intra-arterial vasodilator infusion and intracranial percutaneous transluminal angiography, in delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.

Intracranial stent placement **meets the definition of medical necessity** as part of the endovascular treatment of intracranial aneurysms for members when surgical treatment is not appropriate **AND** standard endovascular techniques do not allow for complete isolation of the aneurysm, (e.g., wide-neck aneurysm of 4 mm or more, or sack-to-neck ratio less than 2:1).

Intracranial flow-diverting stents with FDA approval for the treatment of intracranial aneurysms **meets the definition of medical necessity** as part of the endovascular treatment of intracranial aneurysms that meet anatomic criteria* and are not amenable to surgical treatment or standard endovascular therapy.

*(Flow-diverting stents are indicated for the treatment of large or giant wide-necked intracranial aneurysms, with a size of 10 mm or more and a neck diameter of 4 mm or more, in the internal carotid artery from the petrous to the superior hypophyseal segments.)

The use of endovascular mechanical embolectomy using a device with FDA approval for the treatment of acute ischemic stroke **meets the definition of medical necessity** as part of the treatment of acute ischemic stroke for members who meet **ALL** of the following criteria:

- Have a demonstrated occlusion within the proximal intracranial anterior circulation (intracranial internal carotid artery, or M1 or M2 segments of the middle cerebral artery, or A1 or A2 segments of the anterior cerebral artery); **AND**
- Can receive endovascular mechanical embolectomy within 12 hours of symptom onset **OR** within 24 hours of symptom onset if there is evidence of a mismatch between specific clinical and imaging criteria; **AND**
- Have evidence of substantial and clinically significant neurological deficits (e.g. baseline (post-stroke) National Institutes of Health Stroke Scale (NIHSS) score); **AND**

- Have evidence of salvageable brain tissue in the affected vascular territory (e.g. Alberta Stroke Program Early CT (ASPECTs) score); **AND**
- Have no evidence of intracranial hemorrhage or arterial dissection on CT or MRI imaging.

Endovascular interventions are considered **experimental or investigational** for the treatment of acute ischemic stroke when the above criteria are not met. The evidence is insufficient to determine the effects of the technology on health outcomes.

Intracranial stent placement is considered **experimental or investigational** in the treatment of intracranial aneurysms except as noted above. The evidence is insufficient to determine the effects of the technology on health outcomes.

Intracranial percutaneous transluminal angioplasty with or without stenting is considered **experimental or investigational** in the treatment of atherosclerotic cerebrovascular disease. The evidence is insufficient to determine that the technology is unlikely to improve the net health outcome.

Extracranial Vertebral Artery Disease

Endovascular therapy, including percutaneous transluminal angioplasty with or without stenting, is considered **experimental or investigational** for the management of extracranial vertebral artery diseases. The evidence is insufficient to determine the effects of the technology on health outcomes.

BILLING/CODING INFORMATION:

CPT Coding

61630	Balloon angioplasty, intracranial (e.g., atherosclerotic stenosis), percutaneous (Investigational)
61635	Transcatheter placement of intravascular stent(s), intracranial (e.g., atherosclerotic stenosis), including balloon angioplasty, if performed
61640	Balloon dilatation of intracranial vasospasm, percutaneous; initial vessel (Investigational)
61641	Balloon dilatation of intracranial vasospasm, percutaneous; each additional vessel in same vascular territory (List separately in addition to code for primary procedure) (Investigational)
61642	Balloon dilatation of intracranial vasospasm, percutaneous; each additional vessel in different vascular territory (List separately in addition to code for primary procedure) (Investigational)
61645	Percutaneous arterial transluminal mechanical thrombectomy and/or infusion for thrombolysis, intracranial, any method, including diagnostic angiography, fluoroscopic guidance, catheter placement, and intraprocedural pharmacological thrombolytic injection(s)
0075T	Transcatheter placement of extracranial vertebral artery stent(s), including radiologic supervision and interpretation, open or percutaneous; initial vessel (Investigational)

0076T	Transcatheter placement of extracranial vertebral artery stent(s), including radiologic supervision and interpretation, open or percutaneous; each additional vessel (List separately in addition to code for primary procedure) (Investigational)
-------	---

ICD-10 Diagnosis Codes That Support Medical Necessity for codes 61635, 61645:

I63.00-I63.9	Cerebral infarction due to thrombosis of precerebral arteries
I66.01-I66.9	Occlusion and stenosis of middle cerebral artery
I67.0-I67.9	Other cerebrovascular diseases

REIMBURSEMENT INFORMATION:

Refer to sections entitled [POSITION STATEMENT](#).

PROGRAM EXCEPTIONS:

Federal Employee Program (FEP): Follow FEP guidelines.

State Account Organization (SAO): Follow SAO guidelines.

Medicare Advantage products: The following National Coverage Determination (NCD) was reviewed on the last guideline reviewed date: Percutaneous Transluminal Angioplasty (PTA) (20.7) located at cms.gov.

If this Medical Coverage Guideline contains a step therapy requirement, in compliance with Florida law 627.42393, members or providers may request a step therapy protocol exemption to this requirement if based on medical necessity. The process for requesting a protocol exemption can be found at [Coverage Protocol Exemption Request](#).

DEFINITIONS:

Alberta Stroke Program Early CT (ASPECTs) score- <https://www.mdcalc.com/alberta-stroke-program-early-ct-score-aspects>

National Institutes of Health Stroke Scale (NIHSS) score- <https://www.mdcalc.com/nih-stroke-scale-score-nihss>

RELATED GUIDELINES:

None applicable.

OTHER:

None applicable.

REFERENCES:

1. Abruzzo TA, Tong FC, Waldrop AS, Workman MJ, Cloft HJ, Dion JE. Basilar artery stent angioplasty for symptomatic intracranial athero-occlusive disease: complications and late midterm clinical outcomes. AJNR Am J Neuroradiol. 2007 May;28(5):808-15.

2. Alexander MJ, Zauner A, et al. WEAVE Trial: Final Results in 152 On-Label Patients. *Stroke*. 2019 Apr;50(4). PMID 31125298.
3. ASA/ACCF/HAA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS. Guideline on the Management of Patients with Extracranial Carotid and Vertebral Artery Disease. 2011; accessed at circ.ahajournals.org 02/17/15.
4. Blue Cross Blue Shield Association Evidence Positioning System®. 2.01.54 Endovascular Procedures for Intracranial Arterial Disease (Atherosclerosis and Aneurysms), 05/24.
5. Blue Cross Blue Shield Association Evidence Positioning System®. 7.01.148 Endovascular Therapies for Extracranial Vertebral Artery Disease, 06/24.
6. Bose A, Hartmann M, Henkes H, Liu HM, Teng MM, Szikora I, Berlis A, Reul J, Yu SC, Forsting M, Lui M, Lim W, Sit SP. A novel, self-expanding, nitinol stent in medically refractory intracranial atherosclerotic stenoses: the Wingspan study. *Stroke*. 2007 May;38(5):1531-7. Epub 2007 Mar 29.
7. Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) for Percutaneous Transluminal Angioplasty (PTA) (20.7); accessed at cms.gov.
8. Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, Levine SR, Chaturvedi S, Kasner SE, Benesch CG, Sila CA, Jovin TG, Romano JG; Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. *N Engl J Med*. 2005 Mar 31;352(13):1305-16.
9. Derdeyn CP, Chimowitz MI. Angioplasty and stenting for atherosclerotic intracranial stenosis: rationale for a randomized clinical trial. *Neuroimaging Clin N Am*. 2007 Aug;17(3):355-63, viii-ix. Review.
10. Derdeyn CP, Fiorella D, Lynn MJ, Rumboldt Z, Cloft HJ, Gibson D, Turan TN, Lane BF, Janis LS, Chimowitz MI; Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis Trial Investigators. Mechanisms of stroke after intracranial angioplasty and stenting in the SAMMPRIS trial. *Neurosurgery*. 2013 May;72(5):777-95; discussion 795.
11. Derdeyn CP, Fiorella D, Lynn MJ, Turan TN, Lane BF, Janis LS, Chimowitz MI. Intracranial stenting: SAMMPRIS. *Stroke*. 2013 Jun;44(6 Suppl 1):S41-4.
12. English JD, Yavagal DR, Gupta R, et al. Mechanical thrombectomy-ready comprehensive stroke center requirements and endovascular stroke systems of care: recommendations from the Endovascular Stroke Standards Committee of the Society of Vascular and Interventional Neurology (SVIN). *Interv Neurol*. Mar 2016;4(3-4):138-150.
13. European Stroke Organisation, Tendera M, Aboyans V, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). *Eur Heart J*. Nov 2011;32(22):2851-2906.
14. Fiorella D, Boulos A, et al. The Safety and Effectiveness of the LVIS Stent System for the Treatment of Wide-Necked Cerebral Aneurysms: Final Results of the Pivotal US LVIS Trial. *J Neurointerv Surg*. 2019 Apr;11(4). PMID 30297543.
15. Fiorella D, Derdeyn CP, et al. Detailed analysis of periprocedural strokes in patients undergoing intracranial stenting in Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS). *Stroke*. 2012 Oct;43(10):2682-8.
16. Groschel K, Schaudigel S, Pilgram SM et al. A systematic review on outcome after stenting for intracranial atherosclerosis. *Stroke* 2009; 40(5):e340-7.
17. Henkes H, Miloslavski E, Lowens S, Reinartz J, Liebig T, Kühne D. Treatment of intracranial atherosclerotic stenoses with balloon dilatation and self-expanding stent deployment (WingSpan). *Neuroradiology*. 2005 Mar; 47(3): 222-8. Epub 2005 Mar 15.

18. Higashida RT, Meyers PM, Connors JJ 3rd, Sacks D, Strother CM, Barr JD, Wojak JC, Duckwiler GR; American Society of Interventional and Therapeutic Neuroradiology; Society of Interventional Radiology; American Society of Neuroradiology. Intracranial angioplasty & stenting for cerebral atherosclerosis: a position statement of the American Society of Interventional and Therapeutic Neuroradiology, Society of Interventional Radiology, and the American Society of Neuroradiology. *AJNR Am J Neuroradiol.* 2009; 20:S312-S316. Accessed 06/15/12.
19. Higashida RT, Myers PM. Intracranial angioplasty and stenting for cerebral atherosclerosis: new treatments for stroke are needed! *Neuroradiology* 2006; 48:367-372.
20. Holmstedt CA, Turan TN, Chimowitz MI. Atherosclerotic intracranial arterial stenosis: risk factors, diagnosis, and treatment. *Lancet Neurol.* 2013 Nov;12(11):1106-14.
21. Hurley, Dan. Intracranial Stenting's Risks Over Medical Therapy Prompt Halt of Major Trial. *Neurology Today*, 05 May 2011; Volume 11(9); p 10.
22. Jankowitz BT, Hanel R, et al. Neuroform Atlas Stent System for the Treatment of Intracranial Aneurysm: Primary Results of the Atlas Humanitarian Device Exemption Cohort. *J Neurointerv Surg.* 2019 Aug;11(8). PMID 30670625.
23. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke.* Jul 2014;45(7):2160-2236.
24. Kleindorfer DO, Towfighi A, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. *Stroke.* 2021 Jul;52(7):e364-e467.
25. Kondo, R, Ishihara S, et al. Endovascular Treatment for Acute Ischaemic Stroke Caused by Vertebral Artery Dissection: A Report of Three Cases and Literature Review. *NMC Case Rep J.* 2021 Dec 22;8(1):817-825.
26. Liu X, Dai Q, et al. Endovascular Treatment Versus Standard Medical Treatment for Vertebrobasilar Artery Occlusion (BEST): An Open-Label, Randomised Controlled Trial. *Lancet Neurol.* 2020 Feb;19(2). PMID 31831388.
27. Markus HS, Harshfield EL, Compter A, et al. Stenting for symptomatic vertebral artery stenosis: a preplanned pooled individual patient data analysis. *Lancet Neurol.* Jul 2019; 18(7): 666-673. PMID 31130429.
28. Markus HS, Larsson SC, Dennis J, et al. Vertebral artery stenting to prevent recurrent stroke in symptomatic vertebral artery stenosis: the VIST RCT. *Health Technol Assess.* Aug 2019; 23(41): 1-30. PMID 31422789.
29. Marks MP, Wojak JC, Al-Ali F, Jayaraman M, Marcellus ML, Connors JJ, Do HM. Angioplasty for symptomatic intracranial stenosis: clinical outcome. *Stroke.* 2006 Apr; 37(4):1016-20. Epub 2006 Feb 23.
30. Marks MP. Is there a future for endovascular treatment of intracranial atherosclerotic disease after Stenting and Aggressive Medical Management for Preventing Recurrent Stroke and Intracranial Stenosis (SAMMPRIS)? *Stroke.* 2012 Feb;43(2):580-4. Doi: 10.1161/STROKEAHA.111.645507. Epub 2012 Jan 12.
31. McTaggart RA, Marks MP. The Case for Angioplasty in Patients with Symptomatic Intracranial Atherosclerosis. *Front Neurol.* 2014 Apr 11;5:36.
32. Meyers PM, Schumacher HC, Higashida RT et al. Indications for the performance of intracranial endovascular neurointerventional procedures: a scientific statement from the American Heart Association Council on Cardiovascular Radiology and Intervention, Stroke Council, Council on Cardiovascular Surgery and Anesthesia, Interdisciplinary Council on Peripheral Vascular Disease, and Interdisciplinary Council on Quality of Care and Outcomes Research. *Circulation* 2009; 119(16):2235-49.

33. Nogueira RG, Lobsien D, et al. Thrombectomy With the pRESET vs Solitaire Stent Retrievers as First-Line Large Vessel Occlusion Stroke Treatment: A Randomized Clinical Trial. *JAMA Neurol.* 2024 Feb 1;81(2):170-178.
34. Powers WJ, Derdeyn CP, Biller J, et al. 2015 AHA/ASA Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke.* Jun 29 2015.
35. Powers WJ, Rabinstein AA, Ackerson T et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke.* 2019 Dec;50(12).
36. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke.* Mar 2018;49(3):e46-e110.
37. Siddiq F, Vazquez G, Memon MZ et al. Comparison of primary angioplasty with stent placement for treating symptomatic intracranial atherosclerotic diseases: a multicenter study. *Stroke* 2008; 39(9):2505-10.
38. U.S. Food and Drug Administration (FDA), accessed at fda.gov.
39. Wojak JC, Dunlap DC, Hargrave KR, DeAlvare LA, Culbertson HS, Connors JJ 3rd. Intracranial angioplasty and stenting: long-term results from a single center. *AJNR Am J Neuroradiol.* 2006 Oct;27(9):1882-92.
40. Xu R, Zhang X, et al. Percutaneous transluminal angioplasty and stenting for vertebral artery stenosis. *Cochrane Database Syst Rev.* 2022 May 17;5(5):CD013692.
41. Yeo JYP, Yau CE, et al. Comparing the Impact of Stenting vs. Medical Therapy for Intracranial Arterial Stenosis : A Systematic Review and One-stage and Two-stage Meta-Analysis of Randomized Clinical Trials. *Clin Neuroradiol.* 2024 Jan 3. doi: 10.1007/s00062-023-01370-3. PMID: 38172262.

COMMITTEE APPROVAL:

This Medical Coverage Guideline (MCG) was approved by the Florida Blue Medical Policy and Coverage Committee on 06/27/24.

GUIDELINE UPDATE INFORMATION:

07/15/08	New Medical Coverage Guideline.
09/15/09	Scheduled review; no change in position statement; references updated.
04/15/10	Revision to add rationale for position statement.
09/15/10	Scheduled review; position statement unchanged, references updated.
12/15/11	Reviewed with revision of Position Statement and Coding section; references updated, formatting changes.
08/15/12	Reviewed with no change to Position Statement; references updated.
09/15/13	Scheduled review; position statement unchanged; Program Exceptions section updated; references updated.
08/15/14	Annual review; position statement revised to address endovascular interventions for the treatment of acute ischemic stroke; MCG title revised; references updated.
04/15/15	Revision; position statement, title, description, coding, and references updated; formatting changes.

11/01/15	Revision: ICD-9 Codes deleted.
11/15/15	Revision; position statement, coding, and references updated; formatting changes.
01/01/16	Annual CPT/HCPCS update: codes 61645, 61650, 61651 added.
08/01/17	Revision; Endovascular therapy position statement revised; references updated; formatting changes.
07/15/18	Review; position statements, coding, and references updated.
01/01/19	Annual CPT/HCPCS coding update. Revised codes 61641 & 61642.
07/15/20	Review; position statements maintained and references updated.
07/15/22	Review: Position statements maintained; references updated.
08/21/23	Update to Program Exceptions section.
07/15/24	Review: Position statements maintained; references updated.